公开(公告)号：KR1020070009934A

公开(公告)日：2007-01-19

申请号：KR1020050064571

申请日：2005-07-16

Applicant: 주식회사 씨티씨바이오 ,  신풍제약주식회사

Inventor： 권도우 ,  유세근 ,  이봉상 ,  전홍렬 ,  박수준 ,  김병용 ,  노정렬

IPC: A61K9/22 ,  A61K31/445

CPC classification number: A61K9/2054 ,  A61K9/2027 ,  A61K9/2846 ,  A61K9/2866 ,  A61K31/4525

Abstract: A sustained-release tablet comprising paroxetine hydrochloride is provided to show low initial discharge rate of the paroxetine hydrochloride and be able to discharge the paroxetine hydrochloride at almost zero-order speed for about 12 hours. The sustained-release tablet comprises paroxetine hydrochloride, a high viscous polymer such as a high viscous hydroxypropylmethylcellulose, a mixture polymer consisting of polyvinyl acetate and povidone in a weight ratio of 8:2 and ethyl cellulose, a low viscous hydroxypropylmethylcellulose, and a pharmaceutically acceptable excipient such as a mixture of mannitol and lactose.

Abstract translation: 提供了包含帕罗西汀盐酸盐的缓释片剂，以显示出帕罗西汀盐酸盐的初始排出率低，并且能够以几乎零级速度将帕罗西汀盐酸盐排出约12小时。 缓释片剂包括盐酸帕罗西汀，高粘度聚合物如高粘度羟丙基甲基纤维素，由聚乙酸乙烯酯和聚维酮组成的混合物，其重量比为8:2，乙基纤维素，低粘度羟丙基甲基纤维素和药学上可接受的 赋形剂如甘露糖醇和乳糖的混合物。

公开(公告)号：KR100648739B1

公开(公告)日：2006-11-23

申请号：KR1020040032630

申请日：2004-05-10

Applicant: 신풍제약주식회사

Inventor： 조일환 ,  이철규

IPC: A61K35/62 ,  A61K9/14

Abstract: 본 발명은 구인(룸브리쿠스 루벨루스(
Lumbricus rubellus ))의 조추출물을 수용성 유기용매로 분별침전(fractional precipitation)하고 초여과(ultrafiltration)하는 단계를 포함하여, 항혈전 및 혈전용해 활성을 갖는 단백질분해효소(protease) 분말을 제조하는 방법에 관한 것이다.

公开(公告)号：KR100439731B1

公开(公告)日：2004-07-12

申请号：KR1020010023645

申请日：2001-05-02

Applicant: 신풍제약주식회사

Inventor： 조승열 ,  채종일 ,  홍성태 ,  한신 ,  조일환

IPC: G01N33/53

Abstract: 본 발명은 간흡충, 폐흡충, 유구낭미충 및 고충(Sparganum) 감염증을 동시에 진단할 수 있는 효소면역진단(ELISA: Enzyme-Linked ImmunoSorbent Assay) 키트에 관한 것이다. 본 발명의 키트를 이용하면, 주요 조직내 기생충 감염증을 한 번에 규격화된 방법으로 간편하고 신속·정확하게 진단할 수 있다.

公开(公告)号：KR100399195B1

公开(公告)日：2003-09-26

申请号：KR1020010013859

申请日：2001-03-17

Applicant: 신풍제약주식회사

Inventor： 이성태 ,  한신 ,  박우일 ,  김형태

IPC: C07D501/12

Abstract: PURPOSE: Provided is a process for preparing amorphous form of cefuroxime axetil, thereby producing amorphous form of cefuroxime axetil, which is excellent in elution in a living body and has stability, in high yield and purity. CONSTITUTION: The amorphous cefuroxime axetil represented by the formula(1) is manufactured by the steps of: dissolving cefuroxime axetil in a polar organic solvent; passing CO2 gas therethrough; and adding a water soluble solution containing inorganic salts to precipitate amorphous cefuroxime axetil.

Abstract translation: 用途：提供一种制备无定形头孢呋辛酯的方法，由此制得无定形形式的头孢呋辛酯，其在生物体中洗脱性能优异，并且具有稳定性，高产率和纯度。 构成：由式（1）表示的无定形头孢呋辛酯通过以下步骤制备：将头孢呋辛酯溶解在极性有机溶剂中; 通过二氧化碳气体; 并加入含有无机盐的水溶性溶液以沉淀无定形头孢呋辛酯。

公开(公告)号：KR1020020084850A

公开(公告)日：2002-11-13

申请号：KR1020010023645

申请日：2001-05-02

Applicant: 신풍제약주식회사

Inventor： 조승열 ,  채종일 ,  홍성태 ,  한신 ,  조일환

IPC: G01N33/53

Abstract: PURPOSE: An enzyme-linked immunosorbent assay kit of Clonorchis sinensis., Paragonimus westermani, Cysticerus cellulosae and Sparganum infection syndrome is provided, thereby rapidly and correctly diagnosing the infection of main tissues with parasites. CONSTITUTION: The enzyme-linked immunosorbent assay kit of Clonorchis sinensis., Paragonimus westermani, Cysticerus cellulosae and Sparganum infection syndrome comprises a multi-well microplate or strip containing antigens of Clonorchis sinensis. Paragonimus westermani, Cysticerus cellulosae and Sparganum; a human serum which doesn't react with the antigens of Clonorchis sinensis. Paragonimus westermani, Cysticerus cellulosae and Sparganum as a negative standard serum; and a human serum which specifically and independently reacts with the antigens of Clonorchis sinensis., Paragonimus westermani, Cysticerus cellulosae and Sparganum as a positive standard serum.

Abstract translation: 目的：提供中华支气管炎，Paragonimus westermani，囊性囊性囊炎和Sparganum感染综合征的酶联免疫吸附测定试剂盒，从而快速正确地诊断主要组织与寄生虫的感染。 构成：Clonorchis sinensis，Paragonimus westermani，Cysticerus cellulosae和Sparganum感染综合征的酶联免疫吸附测定试剂盒包括含有Clonorchis sinensis抗原的多孔微孔板或条带。 Paragonimus westermani，Cysticerus cellulosae和Sparganum; 一种不与中华支原体抗原反应的人血清。 Paragonimus westermani，Cysticerus cellulosae和Sparganum作为阴性标准血清; 以及与Clonorchis sinensis，Paragonimus westermani，Cysticerus cellulosae和Sparganum的抗原作为阳性标准血清特异性和独立地反应的人血清。

公开(公告)号：KR1020020073918A

公开(公告)日：2002-09-28

申请号：KR1020010013859

申请日：2001-03-17

Applicant: 신풍제약주식회사

Inventor： 이성태 ,  한신 ,  박우일 ,  김형태

IPC: C07D501/12

Abstract: PURPOSE: Provided is a process for preparing amorphous form of cefuroxime axetil, thereby producing amorphous form of cefuroxime axetil, which is excellent in elution in a living body and has stability, in high yield and purity. CONSTITUTION: The amorphous cefuroxime axetil represented by the formula(1) is manufactured by the steps of: dissolving cefuroxime axetil in a polar organic solvent; passing CO2 gas therethrough; and adding a water soluble solution containing inorganic salts to precipitate amorphous cefuroxime axetil.

Abstract translation: 目的：提供头孢呋辛酯无定形形式的方法，由此生产无机形式的头孢呋辛酯，其在生物体中的洗脱性优异且稳定性高，产率高，纯度高。 构成：由式（1）表示的无定形头孢呋辛酯通过以下步骤制造：将头孢呋辛酯在极性有机溶剂中溶解; 使二氧化碳气体通过; 并加入含有无机盐的水溶性溶液以沉淀无定形头孢呋辛酯。

公开(公告)号：KR1020020046407A

公开(公告)日：2002-06-21

申请号：KR1020000076298

申请日：2000-12-14

Applicant: 신풍제약주식회사

Inventor： 이성태 ,  한신 ,  박우일 ,  주정철 ,  이철규 ,  김혜선

IPC: A61K9/08

CPC classification number: A61K9/0019 ,  A61K31/192 ,  A61K47/02

Abstract: PURPOSE: Provided is a pharmaceutical composition for intramuscular injection containing loxoprofen having excellent anti-inflammatory effects, as an active ingredient, and its pharmaceutically acceptable salts. CONSTITUTION: The pharmaceutical composition for intramuscular injection contains loxoprofen represented by the formula(1) or its pharmaceutically acceptable salts. It is manufactured by dissolving loxoprofen or its pharmaceutically acceptable salt, a stabilizing agent or solution adjuvant in water for injection then sterilizing it.

Abstract translation: 目的：提供含有作为活性成分的优良抗炎作用的洛索丙芬及其药学上可接受的盐的肌内注射用药物组合物。 构成：用于肌内注射的药物组合物含有由式（1）表示的洛索洛芬或其药学上可接受的盐。 它是通过将洛索洛芬或其药学上可接受的盐，稳定剂或溶液佐剂溶解在水中，然后对其进行消毒而制造的。

公开(公告)号：KR1020010057545A

公开(公告)日：2001-07-04

申请号：KR1019990065917

申请日：1999-12-30

Applicant: 신풍제약주식회사

Inventor： 홍성태 ,  이승진 ,  고원규 ,  주정철

IPC: A61K31/495

CPC classification number: A61K9/1652 ,  A61K9/2013 ,  A61K9/2054 ,  A61K31/4985

Abstract: PURPOSE: Anthelmintic compositions capable of controlling the release velocity of praziquantel for effectively exterminating fluke, tapeworm or the like are provided, which show a worms exterminating effect equal to that of conventional formulations by taking medicine only three times a day. CONSTITUTION: The anthelmintic compositions contain praziquantel; polymer material selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose and ethylcellulose; a filler selected from the group consisting of alkyl alcohol, fatty acid or salts thereof; and a binder, wherein the compositions contain 2 to 60% by weight of the polymer material based on the total weight of the compositions.

Abstract translation: 目的：提供能够控制吡喹酮释放速度以有效灭灭恙虫，绦虫等的驱虫剂，其通过每天服用药物显示与常规制剂相同的蠕虫灭活效果。 构成：驱虫组合物含有吡喹酮; 选自羟丙基甲基纤维素，羟丙基纤维素，羟乙基纤维素，甲基纤维素和乙基纤维素的聚合物材料; 选自烷基醇，脂肪酸或其盐的填料; 和粘合剂，其中所述组合物基于组合物的总重量含有2至60重量％的聚合物材料。

公开(公告)号：KR1019980031737A

公开(公告)日：1998-07-25

申请号：KR1019960051297

申请日：1996-10-31

Applicant: 신풍제약주식회사

Inventor： 김철 ,  이성태 ,  노승균 ,  김응배

IPC: A61K31/557

Abstract: 본 발명은 프로스타글란딘 E
1 을 함유하는 안정한 주사제 조성물에 관한 것이다. 더욱 구체적으로, 본 발명은 프로스타글란딘 E
1 을 구연산나트륨/구연산 완충액에 용해시키고 무균여과하여 동결건조시킴으로써 제조되며 장기간 보관시에도 프로스타글란딘 E
1 이 안정하게 유지되는 안정한 주사제 조성물에 관한 것이다.

公开(公告)号：KR100140290B1

公开(公告)日：1998-06-15

申请号：KR1019940027450

申请日：1994-10-26

Applicant: 신풍제약주식회사

Inventor： 서정진 ,  이성태

IPC: A61K9/48 ,  A61K31/505

Abstract: 본 발명은 경구용 백혈병 치료제로서 유용한 시티라빈 옥포스페이트를 함유하는 경질컵셀제에 관한 것이다. 더욱 구체적으로 본 발명은(1) 시타라빈 옥포스페이트, (2) 나트륨라우릴설페이트 및 나트륨도큐세이트 중에서 선택된 계면활성제, (3) 붕해제인 콜로이드성 이산화규소, (4) 알칼리화제인 나트륨시트레이트를 함유함을 특징으로 하는 경질캅셀제에 관한 것이다. 본 발명의 경질 캅셀제는 상기한 바와 같은 특정의 성분들의 조합으로 이루어져 있기 때문에 산성용액중에서도 탁월한 용출성, 붕해성 및 안정성을 제공한다.